Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease (PD), highly impacting on quality-of-life and health-related costs.
Aim of our real-world study was to evaluate the impact of Foslevodopa/Foscarbidopa (LDp/CDp) subcutaneous infusion (CSCI) on nocturia in a group of advanced PD patients.
Seventy-eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale (IPSS) and Nocturia Quality of Life (NQoL) questionnaire were administrated before starting LDp/CDp CSCI and after three months of infusion.
In this cohort, LDp/CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS-UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post-pre changes of IPSS and LEED showed a negative correlation.
This study supports the utility of the overnight dopaminergic stimulation with LDp/CDp CSCI in controlling overactive bladder.
Movement disorders clinical practice. 2026 Mar 19 [Epub ahead of print]
Livia Brusa, Carla Piano, Elias Paolo Casula, Massimo Marano, Antonio Suppa, Alessandro Zampogna, Martina Patera, Stefano Toro, Jacopo Campone, Fabio Viselli, Laura Vacca, Marika Alborghetti, Alessandro Stefani, Francesco Bove
UOC Neurologia, Movement Disorder Clinic, Ospedale S. Eugenio, Rome, Italy., Neurology Unit, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy., Department of System Medicine, University of Tor Vergata, Rome, Italy., Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy., Department of Human Neurosciences, Sapienza University, Rome, Italy., Parkinson's Disease Center, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy., IRCCS San Giovanni, Battista, Rome, Italy., IRCCS San, Raffaele, Rome, Italy.